BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

257 related articles for article (PubMed ID: 32683582)

  • 1. Tumor-derived neomorphic mutations in ASXL1 impairs the BAP1-ASXL1-FOXK1/K2 transcription network.
    Xia YK; Zeng YR; Zhang ML; Liu P; Liu F; Zhang H; He CX; Sun YP; Zhang JY; Zhang C; Song L; Ding C; Tang YJ; Yang Z; Yang C; Wang P; Guan KL; Xiong Y; Ye D
    Protein Cell; 2021 Jul; 12(7):557-577. PubMed ID: 32683582
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mutant ASXL1 cooperates with BAP1 to promote myeloid leukaemogenesis.
    Asada S; Goyama S; Inoue D; Shikata S; Takeda R; Fukushima T; Yonezawa T; Fujino T; Hayashi Y; Kawabata KC; Fukuyama T; Tanaka Y; Yokoyama A; Yamazaki S; Kozuka-Hata H; Oyama M; Kojima S; Kawazu M; Mano H; Kitamura T
    Nat Commun; 2018 Jul; 9(1):2733. PubMed ID: 30013160
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Epigenetic targeted therapy of stabilized BAP1 in ASXL1 gain-of-function mutated leukemia.
    Wang L; Birch NW; Zhao Z; Nestler CM; Kazmer A; Shilati A; Blake A; Ozark PA; Rendleman EJ; Zha D; Ryan CA; Morgan MAJ; Shilatifard A
    Nat Cancer; 2021 May; 2(5):515-526. PubMed ID: 35122023
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Reducing hyperactivated BAP1 attenuates mutant ASXL1-driven myeloid malignancies in human haematopoietic cells.
    Bai J; Chen Z; Chen C; Zhang M; Zhang Y; Song J; Yuan J; Jiang X; Xing W; Yang J; Bai J; Zhou Y
    Cancer Lett; 2021 Oct; 519():78-90. PubMed ID: 34186160
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The BAP1/ASXL2 Histone H2A Deubiquitinase Complex Regulates Cell Proliferation and Is Disrupted in Cancer.
    Daou S; Hammond-Martel I; Mashtalir N; Barbour H; Gagnon J; Iannantuono NV; Nkwe NS; Motorina A; Pak H; Yu H; Wurtele H; Milot E; Mallette FA; Carbone M; Affar el B
    J Biol Chem; 2015 Nov; 290(48):28643-63. PubMed ID: 26416890
    [TBL] [Abstract][Full Text] [Related]  

  • 6. BRCA1-associated protein 1 (BAP1) deubiquitinase antagonizes the ubiquitin-mediated activation of FoxK2 target genes.
    Okino Y; Machida Y; Frankland-Searby S; Machida YJ
    J Biol Chem; 2015 Jan; 290(3):1580-91. PubMed ID: 25451922
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Aberrant histone modifications induced by mutant ASXL1 in myeloid neoplasms.
    Asada S; Kitamura T
    Int J Hematol; 2019 Aug; 110(2):179-186. PubMed ID: 30515738
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Loss of BAP1 function leads to EZH2-dependent transformation.
    LaFave LM; Béguelin W; Koche R; Teater M; Spitzer B; Chramiec A; Papalexi E; Keller MD; Hricik T; Konstantinoff K; Micol JB; Durham B; Knutson SK; Campbell JE; Blum G; Shi X; Doud EH; Krivtsov AV; Chung YR; Khodos I; de Stanchina E; Ouerfelli O; Adusumilli PS; Thomas PM; Kelleher NL; Luo M; Keilhack H; Abdel-Wahab O; Melnick A; Armstrong SA; Levine RL
    Nat Med; 2015 Nov; 21(11):1344-9. PubMed ID: 26437366
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cancer-associated ASXL1 mutations may act as gain-of-function mutations of the ASXL1-BAP1 complex.
    Balasubramani A; Larjo A; Bassein JA; Chang X; Hastie RB; Togher SM; Lähdesmäki H; Rao A
    Nat Commun; 2015 Jun; 6():7307. PubMed ID: 26095772
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Molecular mechanisms by which the mutant ASXL1/BAP1 complex aggravates myeloid leukemia].
    Asada S
    Rinsho Ketsueki; 2020; 61(4):392-405. PubMed ID: 32378586
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Familial and Somatic
    Peng H; Prokop J; Karar J; Park K; Cao L; Harbour JW; Bowcock AM; Malkowicz SB; Cheung M; Testa JR; Rauscher FJ
    Cancer Res; 2018 Mar; 78(5):1200-1213. PubMed ID: 29284740
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Structural basis of histone H2A lysine 119 deubiquitination by Polycomb repressive deubiquitinase BAP1/ASXL1.
    Thomas JF; Valencia-Sánchez MI; Tamburri S; Gloor SL; Rustichelli S; Godínez-López V; De Ioannes P; Lee R; Abini-Agbomson S; Gretarsson K; Burg JM; Hickman AR; Sun L; Gopinath S; Taylor HF; Sun ZW; Ezell RJ; Vaidya A; Meiners MJ; Cheek MA; Rice WJ; Svetlov V; Nudler E; Lu C; Keogh MC; Pasini D; Armache KJ
    Sci Adv; 2023 Aug; 9(32):eadg9832. PubMed ID: 37556531
    [TBL] [Abstract][Full Text] [Related]  

  • 13. MBD5 and MBD6 stabilize the BAP1 complex and promote BAP1-dependent cancer.
    Tsuboyama N; Szczepanski AP; Zhao Z; Wang L
    Genome Biol; 2022 Sep; 23(1):206. PubMed ID: 36180891
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Kinetic Characterization of ASXL1/2-Mediated Allosteric Regulation of the BAP1 Deubiquitinase.
    Peng H; Cassel J; McCracken DS; Prokop JW; Sementino E; Cheung M; Collop PR; Polo A; Joshi S; Mandell JP; Ayyanathan K; Hinds D; Malkowicz SB; Harbour JW; Bowcock AM; Salvino J; Kennedy EJ; Testa JR; Rauscher FJ
    Mol Cancer Res; 2021 Jul; 19(7):1099-1112. PubMed ID: 33731362
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The ASXL-BAP1 axis: new factors in myelopoiesis, cancer and epigenetics.
    Abdel-Wahab O; Dey A
    Leukemia; 2013 Jan; 27(1):10-5. PubMed ID: 23147254
    [TBL] [Abstract][Full Text] [Related]  

  • 16. ASXL1 mutations promote myeloid transformation through loss of PRC2-mediated gene repression.
    Abdel-Wahab O; Adli M; LaFave LM; Gao J; Hricik T; Shih AH; Pandey S; Patel JP; Chung YR; Koche R; Perna F; Zhao X; Taylor JE; Park CY; Carroll M; Melnick A; Nimer SD; Jaffe JD; Aifantis I; Bernstein BE; Levine RL
    Cancer Cell; 2012 Aug; 22(2):180-93. PubMed ID: 22897849
    [TBL] [Abstract][Full Text] [Related]  

  • 17. ASXL1 mutation correction by CRISPR/Cas9 restores gene function in leukemia cells and increases survival in mouse xenografts.
    Valletta S; Dolatshad H; Bartenstein M; Yip BH; Bello E; Gordon S; Yu Y; Shaw J; Roy S; Scifo L; Schuh A; Pellagatti A; Fulga TA; Verma A; Boultwood J
    Oncotarget; 2015 Dec; 6(42):44061-71. PubMed ID: 26623729
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Retracted: Histone H2B ubquitination regulates retinoic acid signaling through the cooperation of ASXL1 and BAP1.
    Lee SW; Youn H; Kim EJ; Um SJ
    Mol Cell; 2013 Jul; 51(2):200-10. PubMed ID: 23850490
    [TBL] [Abstract][Full Text] [Related]  

  • 19. PR-DUB maintains the expression of critical genes through FOXK1/2- and ASXL1/2/3-dependent recruitment to chromatin and H2AK119ub1 deubiquitination.
    Kolovos P; Nishimura K; Sankar A; Sidoli S; Cloos PA; Helin K; Christensen J
    Genome Res; 2020 Aug; 30(8):1119-1130. PubMed ID: 32747411
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Gene Expression Analysis of Pediatric Acute Myeloid Leukemia Identified a Hyperactive ASXL1/BAP1 Axis Linked with Poor Prognosis and over Expressed Epigenetic Modifiers.
    Elyamany G; Akhter A; Kamran H; Rizwan H; Shabani-Rad MT; Alkhayat N; Al Sharif O; Elborai Y; Al Shahrani M; Mansoor A
    Pediatr Hematol Oncol; 2021 Sep; 38(6):581-592. PubMed ID: 33764257
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.